Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160

Futu News13minutes ago · Ratings

Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating

MT Newswires19:39 · Ratings

Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165

Futu News18:34 · Ratings

Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158

Breakings14:25

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

BenzingaDec 22 22:51

Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating

Futu NewsDec 21 03:31 · Ratings